210240-75-8

Basic information

• Product Name: Carbamic acid, (3-aminopentyl)-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, (3-aminopentyl)-, 1,1-dimethylethyl ester (9CI);1-N-Boc-pentane-1,3-diamine-HCl;1-N-Boc-Pentane-1,3-diaMine hydrochloride;tert-butyl N-(3-aminopentyl)carbamate;1-N-Boc-pentane-1,3-diamine;1-N-Boc-3-pentane-1,3-diamine
• CAS NO: 210240-75-8
• Molecular Formula: C₁₀H₂₂N₂O₂
• Molecular Weight: 202.29388
• Product Categories: N-BOC
• Mol File: 210240-75-8.mol

Chemical Properties

• Boiling Point: 299.5±23.0 °C(Predicted)
• Appearance: /
• Density: 0.963±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 12.77±0.46(Predicted)
• CAS DataBase Reference: Carbamic acid, (3-aminopentyl)-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, (3-aminopentyl)-, 1,1-dimethylethyl ester (9CI)(210240-75-8)
• EPA Substance Registry System: Carbamic acid, (3-aminopentyl)-, 1,1-dimethylethyl ester (9CI)(210240-75-8)

Safety Data

• Hazardous Substances Data: 210240-75-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Carbamic acid, (3-aminopentyl)-, 1,1-dimethylethyl ester (9CI) is used as a reagent in organic synthesis for the preparation of various chemical compounds. Its unique structure allows it to participate in a range of chemical reactions, facilitating the synthesis of target molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, Carbamic acid, (3-aminopentyl)-, 1,1-dimethylethyl ester (9CI) is employed as an intermediate in the development of new drugs. Its properties make it a valuable building block for the synthesis of bioactive molecules with potential therapeutic applications.
Safety Precautions:
When handling Carbamic acid, (3-aminopentyl)-, 1,1-dimethylethyl ester (9CI), it is crucial to follow proper safety protocols. As a chemical compound, it may pose certain risks if not handled correctly. Therefore, it is essential to use appropriate personal protective equipment and work in a well-ventilated area to minimize exposure and ensure safety during its use in research and industrial applications.

Upstream product

• 13139-12-3 tert-butyl 2,5-dioxopyrrolidin-1-yl carbonate 
• 589-37-7 1,3-diaminopentane 
• 6627-89-0 tert-butyl phenyl carbonate 

Relevant articles and documents

Reinvestigating Old Pharmacophores: Are 4-Aminoquinolines and Tetraoxanes Potential Two-Stage Antimalarials?

The syntheses and antiplasmodial activities of various substituted aminoquinolines coupled to an adamantane carrier are described. The compounds exhibited pronounced in vitro and in vivo activity against Plasmodium berghei in the Thompson test. Tethering a fluorine atom to the aminoquinoline C(3) position afforded fluoroaminoquinolines that act as intrahepatocytic parasite inhibitors, with compound 25 having an IC50 = 0.31 μM and reducing the liver load in mice by up to 92% at 80 mg/kg dose. Screening our peroxides as inhibitors of liver stage infection revealed that the tetraoxane pharmacophore itself is also an excellent liver stage P. berghei inhibitor (78: IC50 = 0.33 μM). Up to 91% reduction of the parasite liver load in mice was achieved at 100 mg/kg. Examination of tetraoxane 78 against the transgenic 3D7 strain expressing luciferase under a gametocyte-specific promoter revealed its activity against stage IV-V Plasmodium falciparum gametocytes (IC50 = 1.16 ± 0.37 μM). To the best of our knowledge, compounds 25 and 78 are the first examples of either an 4-aminoquinoline or a tetraoxane liver stage inhibitors.

SUBSTITUTED AMINO-BENZIMIDAZOLES, MEDICAMENTS COMPRISING SAID COMPOUND, THEIR USE AND THEIR METHOD OF MANUFACTURE

The present invention relates to substituted amino-benzimidazoles of general formula (1) wherein the groups R1 to R14 and A, are defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases.

ACYCLIC 1,3-DIAMINES AND USES THEREFOR

This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain substituted -acyclic diamines according to Formula (I): or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a combination thereof, wherein: the R groups are as defined herein. The present invention also relates to a pharmaceutical composition and a method of treatment using the compound of Formula (I).